Global tissue diagnostics market forecast to 2028.By product (consumables, equipment), technology (ISH, IHC, slide staining) and disease type (breast cancer, lymphoma, prostate cancer)

Global tissue diagnostics market

DUBLIN, April 4, 2024 (GLOBE NEWSWIRE) — By product (consumables (antibodies, reagents, tissue, probes), equipment (processing systems, scanners)) and technology (ISH, IHC, slide staining) “Global Tissue Diagnostics Market'', Disease Types (Breast Cancer, Lymphoma, Prostate Cancer) – Forecast to 2028'' report has been added. ResearchAndMarkets.com Recruitment.

The global tissue diagnostics market is projected to reach USD 8.4 billion by 2028 from USD 5.6 billion in 2023, at a CAGR of 8.4% during the forecast period. The market growth is driven by factors such as rising incidence of cancer, increasing availability of reimbursement, and technological advancements in tissue diagnostics are the major factors driving the market growth.

Consumables records the largest share in the tissue diagnostics market by product

The product segment of the global tissue diagnostics market is divided into consumables and equipment. By product segment, consumables are expected to account for the largest share of the tissue diagnostics market in 2022. Market growth is primarily driven by increasing government and private funding in life sciences and cancer research, and increasing R&D spending by major pharmaceutical companies. Additionally, the availability of better consumables that provide efficient results and diagnostic accuracy is attributable to the rising demand, resulting in the growth of this segment.

Immunohistochemistry histodiagnostic segment is expected to grow at a significant rate among technologies during the forecast period

The tissue diagnostics market consists of four technology segments: Immunohistochemistry (IHC), In Situ Hybridization (ISH), Digital Pathology and Workflow, and Specialty Staining. The immunohistochemistry technology segment is expected to account for the largest share of the tissue diagnostics market in 2022. A large share of this segment is mainly driven by the demand for immunohistochemistry products due to the growing elderly population and increasing prevalence of cancer disease diabetes, availability of reimbursement for IHC tests, and adoption of digital pathology. It's increasing.

Breast cancer segment holds the largest share in the disease-specific tissue diagnostics market

The global tissue diagnostics market is segmented into breast cancer, gastric cancer, lymphoma, prostate cancer, non-small cell lung cancer, and other diseases. In 2022, the breast cancer segment accounted for the largest share, mainly due to factors such as age, family history, reproductive history, presence of dense breast tissue, lack of physical activity, alcohol consumption, smoking, and radiation exposure. It is something. In particular, the incidence of breast cancers such as ductal carcinoma in situ (DCIS), invasive ductal carcinoma (IDC), and inflammatory breast cancer (IBC) is increasing.

Asia Pacific: Fastest growing region for tissue diagnostics market

The global tissue diagnostics market is segmented into four major regions: North America, Europe, Asia Pacific, and Rest of the World (RoW). Asia Pacific is expected to grow at the highest rate in the tissue diagnostics market during the forecast period. The high growth in this region is due to the large population targeted, the economic growth of the countries in the region, and the rising incidence of cancer in Asian countries.

This report provides insights such as:

story continues

• Analysis of key drivers (increasing cancer incidence, increasing healthcare costs, increasing demand for digital pathology, increasing healthcare costs, infrastructure development for cancer diagnosis, availability of reimbursement) Increasing technological advances in tissue diagnostics are the main factors driving the growth market expansion), constraints (high degree of integration, high cost of diagnostic imaging systems), opportunities (huge opportunities in BRICS countries, towards personalized medicine) challenges (lack of skilled professionals, availability of remanufactured products, stringent regulatory requirements, lack of infrastructure, Trends (increasing number of reagent rental contracts, increasing usage of reagents) in histopathology (low awareness, lack of standardization in low-income countries) impact the growth of the tissue diagnostics market

• Product Development/Innovation: Detailed insights into upcoming technologies, R&D activities, and new product launches in the Tissue Diagnostics market.

• Market Development: Comprehensive Information on Profitable Market – This report analyzes the Tissue Diagnostics market across various regions.

• Market Diversification: Thorough information on new products, unexplored regions, recent developments, and investments in the Tissue Diagnostics market

• Competitive assessment: Organizations such as F. Hoffman La Roche (Switzerland), Danaher Corporation (USA), PHC Holdings, Inc. (Japan), Agilent Technologies (USA), and Thermo Fisher Scientific Inc. (USA) Involved in diagnostic market strategy.

Key attributes:

Main topics covered:

executive summary

• Tissue Diagnostics Market, By Product, 2023 vs. 2028 (USD Billion)

• Tissue Diagnostics Market, By Technology, 2023 vs. 2028 (USD Billion)

• Tissue Diagnostics Market, by Disease Type, 2023 vs. 2028 (USD Billion)

• Tissue Diagnostics Market, by End User, 2023 vs. 2028 (USD Billion)

• Geographic Snapshot of the Tissue Diagnostics Market

premium insights

• Tissue Diagnostics Market Overview – Rising incidence of cancer and infectious diseases will drive market growth during the forecast period

• North America: Tissue Diagnostics Market by Product and Country (2022) – Consumables segment will account for largest market share in 2022

• Tissue Diagnostics Market: Geographical Snapshot – China and India to exhibit highest growth rate during forecast period

• Tissue Diagnostics Market: Regional Composition – Asia Pacific region is projected to grow at the highest CAGR during the forecast period

• Tissue Diagnostics Market: Developed vs. Emerging Countries – Emerging countries will register higher growth rate during the forecast period

Market trend

driver

• Increased incidence of cancer and infectious diseases

• Growing demand for digital pathology

• Increase in medical costs

• Expanding the availability of redemption

• Increase in establishment of private diagnostic centers

restraints

opportunity

• High growth potential in emerging countries

• Growing interest in personalized medicine

• Increase in the number of cancer drug clinical trials

assignment

• lack of skilled professionals

• Availability of refurbished products

• Insufficient standardization of TDX

industry trends

Introduced companies

• F. Hoffman La Roche Co., Ltd.

• Danaher Corporation

• PHC Holdings Co., Ltd.

• Thermo Fisher Scientific Co., Ltd.

• abbot

• Agilent Technologies Co., Ltd.

• Merck KGaA

• Sakura Finetech Japan Co., Ltd.

• Abcam PLC

• Becton, Dickinson and Company (BD)

• Bio SB

• biogenex

• Cell Signaling Technology Co., Ltd.

• Histline Institute

• Three Medical GmbH

• Cellpas Co., Ltd.

• Amos Scientific Pty Ltd.

• Jinhua Yidi Medical Equipment Co., Ltd.

• Medite Medical GmbH

• Deer Path Spa

• Kfbio Konfoong Bioinformation Tech Co. Ltd

• Diagnostic Biosystems Co., Ltd.

• 3D Tech Co., Ltd.

• RWD Life Science Co., Ltd.

• Dakewe

• Sysmex Corporation

• Enzo Life Sciences

• Biocare Medical LLC.

• milestone medical

• BioOptica Milano Spa

For more information on this report, please visit https://www.researchandmarkets.com/r/5tk3de.

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source of international market research reports and market data. We provide the latest data on international and regional markets, key industries, top companies, new products and latest trends.

attachment

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900